Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Petrylak Provides Perspective on the Nationwide Cisplatin/Carboplatin Shortage

August 28th 2023

Daniel P. Petrylak, MD, discusses strategies he and his colleagues at Yale Cancer Center have employed to reduce the effect of the current chemotherapy shortage on patients, and emphasizes the need to reassess current manufacturing strategies in an effort to potentially mitigate future drug shortages.

PROSPECT Trial Confirms Feasibility of De-escalation of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

August 23rd 2023

Michael Cecchini, MD, expands on key updates in gastrointestinal cancer from the 2023 ASCO Annual Meeting, including the clinical significance of findings from the PROSPECT and phase 3 PRODIGE 23 trials of perioperative chemotherapy vs selective standard chemoradiation.

CGX1321 Demonstrates Safety and Promising Activity in Advanced GI Cancers

August 21st 2023

Marios Giannakis, MD, PhD, discusses how targeting the WNT signaling pathway could harness a previously underutilized pathway involved in GI tumor development, spotlights the activity and safety of CGX1321 with or without pembrolizumab in phase 1 studies, and emphasizes the need for continued investigation of CGX1321 to further validate this precision medicine approach.

Talquetamab Helps Usher in Era of Bispecific Antibodies in Relapsed/Refractory Myeloma

August 18th 2023

Ajai Chari, MD, discusses how the FDA approval of talquetamab addresses several unmet needs in relapsed/refractory multiple myeloma and expands on the agent’s efficacy data and safety profile observed in MonumenTAL-1.

Randall Discusses the Importance of Identifying and Managing Chondroblastoma in Clinical Practice

August 16th 2023

R. Lor Randall, MD, FACS, explains the difference between noncancerous chondroblastoma and other bone neoplasms, details the typical diagnosis and treatment of this rare condition, and emphasizes the importance of pediatric and medical oncologists being able to identify it in clinic.

Early Efficacy of BL-B01D1 in a Phase 1 Study Reflects Potential for ADCs in Lung Cancer and Beyond

August 11th 2023

Helena A. Yu, MD, discusses the investigation of BL-B01D1 in patients with advanced solid tumors, the potential significance of this research for those with EGFR-mutant and wild-type disease, and the expanding body of evidence supporting continued antibody-drug conjugate development in non–small cell lung cancer.

SAMETA Trial Evaluates Efficacy of Savolitinib Plus Durvalumab in MET-Driven Papillary RCC

August 10th 2023

The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.

Dostarlimab/Chemo Approval Changes Treatment Paradigm for dMMR/MSI-H Advanced or Recurrent Endometrial Cancer

August 9th 2023

Dana Chase, MD, FACOG, discusses key efficacy, safety, and quality of life data from the RUBY trial supporting the FDA approval of dostarlimab and explains how this approval could help improve the efficacy of current chemotherapy regimens in advanced-stage or recurrent endometrial cancer.

Experts Provide Key Perspectives on the US Cisplatin/Carboplatin Shortage

August 8th 2023

Experts from various institutions were interviewed by OncLive® at the 24th Annual International Lung Cancer Congress® about the ongoing platinum chemotherapy shortage in the United States.

INDIGO Trial Supports Vorasidenib as Effective Targeted Therapeutic in IDH1/2+ Low-Grade Glioma

August 7th 2023

Rimas V. Lukas, MD, reflects on the key points of his presentation delivered at the 2023 Best of ASCO Meeting, which comprised existing unmet needs in low-grade glioma, key efficacy and safety findings from the INDIGO trial, and the viability of vorasidenib-based combination regimens for future investigation.

BMS-986158–Based Combos May Provide Another Viable Treatment Approach in Myelofibrosis

August 4th 2023

Haifa Kathrin Al-Ali, MD, provides background on the phase 1/2 study of BMS-986158, presents initial efficacy and safety data from the study, and discusses her hope that novel combination regimens like these could achieve the challenging goal of disease modification in myelofibrosis in the future.

Global Consensus-Finding Meeting Aims to Improve the Management of Chondrosarcoma Complications

August 4th 2023

R. Lor Randall, MD, FACS, provides details about the 2024 Birmingham Orthopedic Oncology Meeting and its main topic of discussion, explains the rationale for its inception, and emphasizes the importance of this meeting for orthopedic oncologists treating chondrosarcoma.

Investigation of Ubamatamab With or Without Cemiplimab Continues in Recurrent Ovarian Cancer

August 3rd 2023

The preliminary efficacy, safety, and optimal dose of the MUC16xCD3 bispecific antibody ubamatamab alone or in combination with cemiplimab-rwlc continues to be explored in patients with advanced platinum-resistant ovarian cancer in the phase 2 portion of an ongoing, first-in-human, phase 1/2 study.

Intravenous PRGN-3005 Plus Lymphodepletion Shows Early Promise in Ovarian Cancer

August 2nd 2023

Mary “Nora” Disis, MD, expands on key findings from the phase 1/1b study of PRGN-3005, discusses next steps for the trial, and explains how this research aids efforts to effectively utilize CAR T-cell therapy in ovarian cancer and other solid tumors.

Real-World Outcomes With Brexu-Cel Are Consistent With Clinical Data in R/R MCL, Regardless of Prior Treatment

August 2nd 2023

Swetha Kambhampati, MD, explains the need for real-world data on responses to brexu-cel in patients with relapsed/refractory MCL, compares safety and efficacy data from the subgroup analysis with prior results from ZUMA-2, and discusses how these findings support more long-term follow-up in this population.

ERASur Study Evaluates Total Ablative Therapy Plus Systemic Treatment in mCRC

August 1st 2023

The safety and efficacy of adding total ablative therapy of all disease sites to standard systemic treatment is being investigated in patients with limited metastatic colorectal cancer as part of the ongoing phase 3 ERASur study.

Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

August 1st 2023

Alex Herrera, MD, discussed key data from the SWOG S1826 trial and other important research in hematologic malignancies presented at the 2023 ASCO Annual Meeting.

ASCO Presentations Indicate Bright Future For Immunotherapy Combinations in Soft Tissue Sarcoma

July 31st 2023

Jonathan C. Trent, MD, PhD, discusses data from 2 phase 2 trials of immunotherapy in soft tissue sarcoma, as well as their clinical significance.

Analysis Helps Distinguish the Molecular Profile of Intraductal Carcinoma of the Prostate

July 31st 2023

Benjamin Miron, MD, explains the purpose of studying the molecular profile of intraductal carcinoma of the prostate, expands on the potential prognostic and targetable alterations identified in patients with this histology, and discusses the planned cohort expansion and analysis of RNA signatures in this population.

Up-front Testing Is Imperative for Treatment Decisions in RET+ NSCLC

July 29th 2023

Deborah B. Doroshow, MD, PhD, discusses the efficacy and toxicity profiles of pralsetinib and selpercatinib and how they influence treatment selection for patients with RET fusion–positive non–small cell lung cancer, and provides insight on several areas of ongoing or potential research in lung cancer.